X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-10-02 | VRTX | Biller Jonathan | EVP, GC | S - Sale | $461.66 | -999 | 16,651 | -6% | -$461,198 | ||||||
2024-08-30 | VRTX | Leiden Jeffrey M | Exec COB | S - Sale | $499.00 | -3,784 | 10,434 | -27% | -$1,888,216 | ||||||
D | 2024-08-30 | VRTX | Bhatia Sangeeta N. | Dir | S - Sale+OE | $500.00 | -646 | 4,435 | -13% | -$323,000 | |||||
D | 2024-08-08 | VRTX | Bhatia Sangeeta N. | Dir | S - Sale+OE | $466.29 | -1,292 | 4,435 | -23% | -$602,447 | |||||
2024-08-07 | VRTX | Bozic Carmen | EVP, CMO | S - Sale | $476.75 | -2,280 | 23,259 | -9% | -$1,086,990 | ||||||
D | 2024-08-01 | VRTX | Sachs Bruce I | Dir | S - Sale+OE | $508.00 | -5,295 | 40,000 | -12% | -$2,689,860 | |||||
2024-07-30 | VRTX | Kewalramani Reshma | CEO, Pres | S - Sale | $505.00 | -15,202 | 90,970 | -14% | -$7,677,010 | ||||||
2024-07-24 | VRTX | Bozic Carmen | EVP, CMO | S - Sale | $488.46 | -2,280 | 25,539 | -8% | -$1,113,689 | ||||||
2024-07-22 | VRTX | Kewalramani Reshma | CEO, Pres | S - Sale | $497.00 | -15,202 | 106,172 | -13% | -$7,555,394 | ||||||
2024-07-10 | VRTX | Bozic Carmen | EVP, CMO | S - Sale | $487.34 | -2,280 | 27,819 | -8% | -$1,111,135 | ||||||
2024-06-26 | VRTX | Bozic Carmen | EVP, CMO | S - Sale | $471.72 | -2,280 | 30,099 | -7% | -$1,075,522 | ||||||
2024-06-12 | VRTX | Bozic Carmen | EVP, CMO | S - Sale | $478.00 | -2,280 | 32,379 | -7% | -$1,089,840 | ||||||
2024-06-12 | VRTX | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Offi | S - Sale | $478.00 | -7,288 | 15,972 | -31% | -$3,483,664 | ||||||
2024-06-03 | VRTX | Wagner Charles F Jr | EVP, CFO | S - Sale | $460.00 | -3,250 | 47,137 | -6% | -$1,495,000 | ||||||
2024-06-03 | VRTX | Tatsis Ourania | EVP, Chief Reg., Quality Offic | S - Sale | $460.00 | -2,175 | 49,098 | -4% | -$1,000,500 | ||||||
M | 2024-05-30 | VRTX | Tatsis Ourania | EVP, Chief Reg., Quality Offic | S - Sale | $441.99 | -4,600 | 51,273 | -8% | -$2,033,159 | |||||
2024-05-29 | VRTX | Bozic Carmen | EVP, CMO | S - Sale | $445.56 | -2,280 | 34,659 | -6% | -$1,015,877 | ||||||
2024-05-28 | VRTX | Wagner Charles F Jr | EVP, CFO | S - Sale | $454.79 | -3,250 | 50,387 | -6% | -$1,478,068 | ||||||
D | 2024-05-24 | VRTX | Kewalramani Reshma | CEO, Pres | S - Sale+OE | $457.00 | -1,565 | 121,374 | -1% | -$715,205 | |||||
D | 2024-05-22 | VRTX | Sachs Bruce I | Dir | S - Sale+OE | $448.00 | -7,073 | 40,000 | -15% | -$3,168,704 | |||||
2024-05-20 | VRTX | Kewalramani Reshma | CEO, Pres | S - Sale | $447.00 | -15,202 | 121,374 | -11% | -$6,795,294 | ||||||
2024-05-15 | VRTX | Sachdev Amit | EVP Chief Patient, Ext Af Off | S - Sale | $430.93 | -32 | 62,772 | 0% | -$13,790 | ||||||
2024-05-15 | VRTX | Arbuckle Stuart A | EVP, COO | S - Sale | $430.93 | -69 | 49,831 | 0% | -$29,734 | ||||||
2024-05-15 | VRTX | Altshuler David | EVP, Chief Scientific Officer | S - Sale | $430.93 | -54 | 25,813 | 0% | -$23,270 | ||||||
2024-05-02 | VRTX | Bhatia Sangeeta N. | Dir | S - Sale | $402.95 | -467 | 4,435 | -10% | -$188,178 | ||||||
2024-04-02 | VRTX | Ambrose Kristen | SVP, Chief Accounting Officer | S - Sale | $419.00 | -240 | 7,500 | -3% | -$100,560 | ||||||
2024-02-26 | VRTX | Tatsis Ourania | EVP, Chief Reg., Quality Offic | S - Sale | $425.70 | -354 | 55,804 | -1% | -$150,698 | ||||||
2024-02-26 | VRTX | Sachdev Amit | EVP Chief Patient, Ext Af Off | S - Sale | $425.70 | -3,004 | 62,772 | -5% | -$1,278,803 | ||||||
2024-02-26 | VRTX | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Offi | S - Sale | $425.70 | -883 | 15,972 | -5% | -$375,893 | ||||||
2024-02-26 | VRTX | Arbuckle Stuart A | EVP, COO | S - Sale | $425.70 | -5,034 | 49,831 | -9% | -$2,142,974 | ||||||
2024-02-26 | VRTX | Ambrose Kristen | SVP, Chief Accounting Officer | S - Sale | $425.70 | -883 | 7,965 | -10% | -$375,893 | ||||||
2024-02-26 | VRTX | Altshuler David | EVP, Global Research, CSO | S - Sale | $425.70 | -4,239 | 25,813 | -14% | -$1,804,542 | ||||||
2024-02-21 | VRTX | Tatsis Ourania | EVP, Chief Reg., Quality Offic | S - Sale | $421.77 | -360 | 59,467 | -1% | -$151,837 | ||||||
2024-02-21 | VRTX | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Offi | S - Sale | $421.77 | -1,201 | 18,509 | -6% | -$506,546 | ||||||
2024-02-21 | VRTX | Arbuckle Stuart A | EVP, COO | S - Sale | $421.77 | -3,603 | 59,579 | -6% | -$1,519,637 | ||||||
2024-02-21 | VRTX | Altshuler David | EVP, Global Research, CSO | S - Sale | $421.77 | -3,002 | 34,022 | -8% | -$1,266,154 | ||||||
2024-02-20 | VRTX | Tatsis Ourania | EVP, Chief Reg., Quality Offic | S - Sale | $420.79 | -480 | 59,827 | -1% | -$201,979 | ||||||
2024-02-20 | VRTX | Sachdev Amit | EVP Chief Patient, Ext Af Off | S - Sale | $420.79 | -4,254 | 71,436 | -6% | -$1,790,041 | ||||||
2024-02-20 | VRTX | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Offi | S - Sale | $420.79 | -801 | 19,710 | -4% | -$337,053 | ||||||
2024-02-20 | VRTX | Arbuckle Stuart A | EVP, COO | S - Sale | $420.79 | -4,804 | 63,182 | -7% | -$2,021,475 | ||||||
2024-02-20 | VRTX | Altshuler David | EVP, Global Research, CSO | S - Sale | $420.79 | -4,002 | 37,024 | -10% | -$1,684,002 | ||||||
M | 2024-02-14 | VRTX | Leiden Jeffrey M | Exec COB | S - Sale | $419.10 | -9,011 | 18,336 | -33% | -$3,776,528 | |||||
M | 2024-02-12 | VRTX | Leiden Jeffrey M | Exec COB | S - Sale | $419.42 | -3,393 | 27,347 | -11% | -$1,423,104 | |||||
2024-02-12 | VRTX | Sachdev Amit | EVP Chief Patient, Ext Af Off | S - Sale | $420.24 | -3,222 | 81,811 | -4% | -$1,354,013 | ||||||
2024-02-12 | VRTX | Biller Jonathan | EVP, GC | S - Sale | $418.77 | -1,738 | 18,280 | -9% | -$727,822 | ||||||
2024-02-12 | VRTX | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Offi | S - Sale | $420.24 | -913 | 23,137 | -4% | -$383,679 | ||||||
2024-02-12 | VRTX | Arbuckle Stuart A | EVP, COO | S - Sale | $420.24 | -4,295 | 75,858 | -5% | -$1,804,931 | ||||||
2024-02-12 | VRTX | Ambrose Kristen | SVP, Chief Accounting Officer | S - Sale | $420.24 | -1,374 | 9,676 | -12% | -$577,410 | ||||||
2024-02-12 | VRTX | Altshuler David | EVP, Global Research, CSO | S - Sale | $420.24 | -3,145 | 47,588 | -6% | -$1,321,655 | ||||||
2024-01-08 | VRTX | Leiden Jeffrey M | Exec COB | S - Sale | $419.07 | -6,648 | 2,863 | -70% | -$2,785,977 | ||||||
2024-01-02 | VRTX | Wagner Charles F Jr | EVP, CFO | S - Sale | $405.00 | -3,000 | 43,693 | -6% | -$1,215,000 | ||||||
D | 2023-12-15 | VRTX | Kewalramani Reshma | CEO, Pres | S - Sale+OE | $407.00 | -17,135 | 108,711 | -14% | -$6,973,945 | |||||
2023-12-13 | VRTX | Leiden Jeffrey M | Exec COB | S - Sale | $399.42 | -13,354 | 9,511 | -58% | -$5,333,799 | ||||||
2023-12-13 | VRTX | Kewalramani Reshma | CEO, Pres | S - Sale | $397.00 | -5,098 | 108,711 | -4% | -$2,023,906 | ||||||
D | 2023-12-13 | VRTX | Arbuckle Stuart A | EVP, COO | S - Sale+OE | $399.00 | -8,603 | 56,696 | -13% | -$3,432,597 | |||||
2023-11-20 | VRTX | Wagner Charles F Jr | EVP, CFO | S - Sale | $349.88 | -3,000 | 46,693 | -6% | -$1,049,640 | ||||||
2023-11-15 | VRTX | Sachdev Amit | EVP Chief Patient, Ext Af Off | S - Sale | $369.92 | -35 | 66,261 | 0% | -$12,947 | ||||||
2023-11-15 | VRTX | Altshuler David | EVP, Global Research, CSO | S - Sale | $369.92 | -19 | 32,038 | 0% | -$7,028 | ||||||
2023-11-14 | VRTX | Bozic Carmen | EVP, CMO | S - Sale | $380.82 | -5,650 | 29,302 | -16% | -$2,151,633 | ||||||
2023-11-13 | VRTX | Kewalramani Reshma | CEO, Pres | S - Sale | $377.00 | -5,097 | 113,809 | -4% | -$1,921,569 | ||||||
D | 2023-11-06 | VRTX | Sachs Bruce I | Dir | S - Sale+OE | $385.00 | -11,250 | 40,000 | -22% | -$4,331,250 | |||||
2023-10-31 | VRTX | Bozic Carmen | EVP, CMO | S - Sale | $355.92 | -5,651 | 34,952 | -14% | -$2,011,304 | ||||||
2023-10-17 | VRTX | Bozic Carmen | EVP, CMO | S - Sale | $373.25 | -5,651 | 40,603 | -12% | -$2,109,236 | ||||||
2023-10-17 | VRTX | Bhatia Sangeeta N. | Dir | S - Sale | $375.00 | -243 | 3,901 | -6% | -$91,125 | ||||||
2023-10-16 | VRTX | Leiden Jeffrey M | Exec COB | S - Sale | $374.00 | -12,962 | 22,865 | -36% | -$4,847,788 | ||||||
2023-10-06 | VRTX | Bhatia Sangeeta N. | Dir | S - Sale | $360.00 | -242 | 4,144 | -6% | -$87,120 | ||||||
2023-10-03 | VRTX | Bozic Carmen | EVP, CMO | S - Sale | $345.28 | -5,651 | 46,254 | -11% | -$1,951,177 | ||||||
2023-10-02 | VRTX | Biller Jonathan | EVP, GC | S - Sale | $346.76 | -610 | 10,569 | -5% | -$211,524 | ||||||
2023-09-19 | VRTX | Bozic Carmen | EVP, CMO | S - Sale | $351.00 | -5,651 | 51,905 | -10% | -$1,983,501 | ||||||
2023-09-05 | VRTX | Bozic Carmen | EVP, CMO | S - Sale | $352.66 | -5,651 | 57,556 | -9% | -$1,992,882 | ||||||
2023-08-23 | VRTX | Tatsis Ourania | EVP, Chief Reg., Quality Offic | S - Sale | $355.00 | -2,500 | 48,637 | -5% | -$887,500 | ||||||
D | 2023-08-10 | VRTX | Kearney Terrence C | Dir | S - Sale+OE | $350.00 | -10,000 | 6,536 | -60% | -$3,500,000 | |||||
2023-08-10 | VRTX | Tatsis Ourania | EVP, Chief Reg., Quality Offic | S - Sale | $345.79 | -5,750 | 51,137 | -10% | -$1,988,293 | ||||||
2023-08-10 | VRTX | Sachdev Amit | EVP, Chief Patient Officer | S - Sale | $350.00 | -10,031 | 66,261 | -13% | -$3,510,850 | ||||||
2023-08-09 | VRTX | Altshuler David | EVP, Global Research, CSO | S - Sale | $345.51 | -63 | 32,038 | 0% | -$21,767 | ||||||
2023-08-09 | VRTX | Bhatia Sangeeta N. | Dir | S - Sale | $345.51 | -242 | 4,386 | -5% | -$83,613 | ||||||
D | 2023-07-17 | VRTX | Sachs Bruce I | Dir | S - Sale+OE | $356.75 | -11,250 | 40,000 | -22% | -$4,013,459 | |||||
2023-07-17 | VRTX | Kewalramani Reshma | CEO, Pres | S - Sale | $355.00 | -7,828 | 118,906 | -6% | -$2,778,940 | ||||||
D | 2023-06-15 | VRTX | Arbuckle Stuart A | EVP, COO | S - Sale+OE | $349.00 | -8,603 | 56,696 | -13% | -$3,002,447 | |||||
2023-05-30 | VRTX | Arbuckle Stuart A | EVP, COO | S - Sale | $329.82 | -82 | 56,696 | 0% | -$27,045 | ||||||
2023-05-30 | VRTX | Ambrose Kristen | SVP, Chief Accounting Officer | S - Sale | $329.82 | -289 | 6,838 | -4% | -$95,318 | ||||||
M | 2023-05-05 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $350.00 | -3,272 | 32,038 | -9% | -$1,145,213 | |||||
M | 2023-05-05 | VRTX | Leiden Jeffrey M | Exec COB | S - Sale | $349.25 | -2,004 | 35,827 | -5% | -$699,887 | |||||
M | 2023-05-02 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $350.71 | -4,403 | 35,310 | -11% | -$1,544,187 | |||||
M | 2023-05-02 | VRTX | Leiden Jeffrey M | Exec COB | S - Sale | $349.98 | -10,958 | 37,831 | -22% | -$3,835,062 | |||||
2023-05-02 | VRTX | Bhatia Sangeeta N. | Dir | S - Sale | $348.28 | -580 | 4,628 | -11% | -$202,004 | ||||||
2023-04-27 | VRTX | Kewalramani Reshma | CEO, Pres | S - Sale | $339.08 | -3,317 | 126,652 | -3% | -$1,124,726 | ||||||
2023-04-12 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $326.70 | -7,567 | 39,713 | -16% | -$2,472,164 | ||||||
D | 2023-04-12 | VRTX | Sachs Bruce I | Dir | S - Sale+OE | $326.73 | -21,300 | 40,000 | -35% | -$6,959,422 | |||||
2023-04-04 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $315.81 | -522 | 47,280 | -1% | -$164,854 | ||||||
2023-03-24 | VRTX | Wagner Charles F Jr | EVP, CFO | S - Sale | $305.38 | -1,768 | 49,611 | -3% | -$539,912 | ||||||
2023-03-17 | VRTX | Wagner Charles F Jr | EVP, CFO | S - Sale | $296.39 | -2,000 | 51,379 | -4% | -$592,786 | ||||||
2023-03-16 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $300.59 | -2,746 | 49,268 | -5% | -$825,423 | ||||||
M | 2023-03-10 | VRTX | Wagner Charles F Jr | EVP, CFO | S - Sale | $291.98 | -4,754 | 53,379 | -8% | -$1,388,054 | |||||
2023-02-27 | VRTX | Tatsis Ourania | EVP, Chief Reg., Quality Offic | S - Sale | $287.48 | -354 | 56,805 | -1% | -$101,768 | ||||||
2023-02-27 | VRTX | Arbuckle Stuart A | EVP, COO | S - Sale | $287.47 | -5,034 | 56,696 | -8% | -$1,447,143 | ||||||
2023-02-27 | VRTX | Ambrose Kristen | SVP, Chief Accounting Officer | S - Sale | $287.55 | -1,207 | 7,303 | -14% | -$347,072 | ||||||
2023-02-27 | VRTX | Altshuler David | EVP, Global Research, CSO | S - Sale | $287.51 | -4,238 | 32,038 | -12% | -$1,218,449 | ||||||
2023-02-22 | VRTX | Arbuckle Stuart A | EVP, COO | S - Sale | $294.33 | -2,401 | 66,444 | -3% | -$706,679 | ||||||
2023-02-21 | VRTX | Tatsis Ourania | EVP, Chief Reg., Quality Offic | S - Sale | $293.75 | -480 | 60,467 | -1% | -$141,002 |
A | Amended filing |
D | Derivative transaction in filing (usually option exercise) |
E | Error detected in filing |
M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
S - Sale | Sale of securities on an exchange or to another person |
S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
P - Purchase | Purchase of securities on an exchange or from another person |